TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M

Preliminary Fourth Quarter and Full Year 2024 Updates: BRIUMVI U.S. net product revenue expected to be $103.6M and $310M for the fourth quarter and full year of 2024, respectively; Year-end 2024 cash position of approximately $310M